Lymphoma News

There are several chemotherapy and targeted anticancer drugs approved or under investigation for the treatment of lymphoma. Unlike traditional chemotherapy that is administered intravenously (IV) in a hospital or clinic, oral therapies are administered via a pill, taken at home…

Axicabtagene ciloeucel has been approved for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).

When Chris Gorelik received news that his central nervous system lymphoma would leave him with months to live, he sought a second opinion and took a chance on a new treatment protocol — to give him a fighting chance to see his children grow up.

Emily Tonorezos, MD, MPH, Director of the Office of Cancer Survivorship at the National Cancer Institute (NCI), in the Division of Cancer Control & Population Sciences, shares what she and the agency are doing to raise awareness of and address issues that cancer survivors may face, as well as future directions in cancer survivorship research.

With telemedicine trending to be a mainstay in how healthcare professionals treat patients, Ameet Doshi, MD, MBA, Lead Hospitalist for Telemedicine at HealthPartners, shares what is contributing to the surge and how it affects lymphoma patients and survivors.

Lisocabtagene maraleucel (BREYANZI) is the fourth chimeric antigen receptor (CAR) T cell therapy approved for certain types of non-Hodgkin lymphoma (NHL).

Umbralisib (UKONIQ, TG Therapeutics), a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon, has been approved for relapsed or refractory marginal zone lymphoma and follicular lymphoma.

Ask the Doctor: Should CLL patients receive the COVID vaccine while they are on treatment with BTK inhibitors considering that they have to stay on them indefinitely? As of January 2021, there are two COVID-19 vaccines that have been approved…

Peripheral T-cell lymphoma (PTCL) is an aggressive (fast-growing) form of non-Hodgkin lymphoma which has typically been associated with having no standard of care. For most subtypes of PTCL, the initial treatment is typically a combination chemotherapy regimen, such as CHOP…

U.S. Food and Drug Administration (FDA) approved the first biomarker-driven therapy for pediatric ALCL.